Abstract
The Monogenic Network of the Global Parkinson’s Genetics Program (GP2) aims to create an efficient infrastructure to accelerate the identification of novel genetic causes of Parkinson’s disease (PD) and to improve our understanding of already identified genetic causes, such as reduced penetrance and variable clinical expressivity of known disease-causing variants. We aim to perform short- and long-read whole-genome sequencing for up to 10,000 patients with parkinsonism.
Competing Interest Statement
C. Klein has received grant support from the Michael J. Fox Foundation for Parkinson's Research and the Aligning Science Across Parkinson's Initiative. She serves as a medical advisor to Centogene and Retromer Therapeutics and has received a speaker's honorarium from Desitin Pharma. S.-Y. Lim received grants from the Michael J. Fox Foundation and the Malaysian Ministry of Education Fundamental Research Grant Scheme. A. Singleton and C. Blauwendraat are supported by the Intramural Research Program of the National Institute on Aging and have received grant support from the Michael J. Fox Foundation for Parkinson's Research and the Aligning Science Across Parkinson's Initiative. A. Singleton has received royalty payments related to a diagnostic for stroke. M. Nalls is a consultant employed by Data Tecnica International. Data Tecnica is engaged in a consulting agreement with the US National Institutes of Health.
Funding Statement
This research is supported by the Aligning Science Across Parkinson's Initiative and the Michael J. Fox Foundation for Parkinson's Research. Data used in the preparation of this article were obtained from Global Parkinson's Genetics Program (GP2). GP2 is funded by the Aligning Science Against Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Every single Ethics committee/IRB of every center participating in this study gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
GP2 has partnered with the Accelerating Medicines Partnership - Parkinson's Disease (AMP-PD; https://amp-pd.org) to share data generated by GP2. The first GP2 data was released to the AMP-PD platform in December 2021, and there will be data releases at regular intervals as the project continues.
